The impact of clinical factors and SARS-CoV-2 variants on antibody production in vaccinated German healthcare professionals infected either with the Delta or the Omicron variant

• Verfasst von: Gerhards, Catharina [VerfasserIn]
• Verfasst von: Steingass, Marlene [VerfasserIn]
• Verfasst von: Heininger, Alexandra [VerfasserIn]
• Verfasst von: Lange, Bettina [VerfasserIn]
• Verfasst von: Hetjens, Michael [VerfasserIn]
• Verfasst von: Gerigk, Marlis [VerfasserIn]
• Verfasst von: Neumaier, Michael [VerfasserIn]
• Verfasst von: Evliyaoglu, Osman [VerfasserIn]
• Verfasst von: Kittel, Maximilian [VerfasserIn]
• Titel: The impact of clinical factors and SARS-CoV-2 variants on antibody production in vaccinated German healthcare professionals infected either with the Delta or the Omicron variant
• Verf.angabe: Catharina Gerhards, Marlene Steingass, Alexandra Heininger, Bettina Lange, Michael Hetjens, Marlis Gerigk, Michael Neumaier, Osman Evliyaoglu and Maximilian Kittel
• E-Jahr: 2024
• Jahr: 5 February 2024
• Umfang: 17 S.
• Illustrationen: Illustrationen
• Fussnoten: Gesehen am 20.03.2024
• Titel Quelle: Enthalten in: Vaccines
• Ort Quelle: Basel : MDPI, 2013
• Jahr Quelle: 2024
• Band/Heft Quelle: 12(2024), 2, Artikel-ID 163, Seite 1-17
• ISSN Quelle: 2076-393X
• DOI: doi:10.3390/vaccines12020163
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: anti-N abs
• Sach-SW: anti-S1/RBS
• Sach-SW: anti-SARS-CoV-2 antibodies
• Sach-SW: COVID-19 after vaccination
• Sach-SW: SARS-CoV-2 vaccination
• Sach-SW: serological immune response
• Sach-SW: vaccination breakthrough
• K10plus-PPN: 1883895154

Abstract

Background: The aim of the rapid introduction of vaccines during the COVID-19 pandemic was a reduction in SARS-CoV-2 transmission and a less frequent occurrence of severe COVID-19 courses. Thus, we evaluated COVID-19 severity in vaccinated individuals to examine variant-specific symptom characteristics and their clinical impact on the serological immune response. Methods: A total of 185 individuals previously vaccinated against and infected with the SARS-CoV-2 Delta (B.1.617.2) or Omicron (BA.4 and BA.5) variant, were enrolled for anti-SARS-CoV-2 anti-N- and anti-RBD/S1-Ig level detection. A structured survey regarding medical history was conducted. Results: In 99.5 percent of cases, outpatient treatment was satisfactory. Specific symptoms associated with variants included ageusia and anosmia in patients with Delta infections and throat pain in Omicron infections. Among Delta-infected individuals with specific symptoms, significantly higher levels of anti-N antibodies were observed. Conclusion: Our study identified variant-specific differences in the amount of SARS-CoV-2 antibody production and COVID-19 symptoms. Despite this, vaccinated individuals with Omicron or Delta infections generally experienced mild disease courses. Additionally, asymptomatic individuals exhibit lower anti-SARS-CoV-2 antibody levels, indicating a clinical correlation between disease-specific antibodies and distinct symptoms, particularly in the case of the Delta variant. In follow-up studies, exploring post-COVID syndrome and focusing on cognitive symptoms in the acute phase of Omicron infections is crucial as it has the potential to longitudinally impact the lives of those affected.